Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.66 |
| ▸ | TACR2 | P21452 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989807 | 0.91 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4990149 | 0.91 | TACR3 (0.79) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14092941 | 0.90 | TACR3 (0.69) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4996320 | 0.87 | TACR3 (0.62) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14092925 | 0.84 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4967704 | 0.82 | TACR3 (0.74) | TACR3TACR2 | |
| SCHEMBL4966074 | 0.82 | TACR3 (0.74) | TACR3TACR2 | |
| SCHEMBL4986681 | 0.82 | TACR3 (0.72) | TACR3TACR2 | |
| SCHEMBL4966460 | 0.82 | TACR3 (0.72) | TACR3TACR2 | |
| SCHEMBL14092937 | 0.82 | TACR3 (0.75) | TACR3TACR2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194622-A1 | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1896418-A1 | QUINOLINE 3 -SULFONATE ESTERS AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137789-A1 | Quinoline 3 -sulfonate esters as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194622-A1 | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators | KCNQ3, KCNA3, GPR3 | TACR3 9/4885TACR2 6/4885CYP1A2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.